I’ve had this conversation enough times that I’ve stopped framing it as "which one wins." Tirzepatide produces more weight loss, yes, the trials are pretty clear, and I’ll get into the numbers. But most of my patients asking this question aren’t running a clinical trial. They’re trying to figure out which medication they can actually get, afford, and stay on. That changes the analysis considerably.
Wegovy and Ozempic are the semaglutide brands. Zepbound and Mounjaro are tirzepatide. Weekly injections, both of them, and both produce real results, not supplement results, actual clinically meaningful outcomes. Where they differ is at the molecular level, and that difference ends up mattering more than I would have initially guessed when tirzepatide first arrived.
The Mechanism Difference
Semaglutide works by mimicking GLP-1, a hormone your gut releases naturally after you eat. It tells your brain you're full, slows things down in the stomach, helps with insulin. Every drug in this class does some version of that. That's the shared foundation.
Tirzepatide adds a second hormone to the mix. GIP, glucose-dependent insulinotropic polypeptide, is another signal involved in appetite and fat metabolism. Eli Lilly built tirzepatide to hit both receptors in one molecule. The effect, in practice, is stronger appetite suppression and more weight loss than you get from GLP-1 alone. It's not a bigger dose of the same thing. It's genuinely hitting different biology, which is why the gap between the two drugs in the efficacy trials isn't small.
The Numbers
The STEP 1 trial put semaglutide at 2.4mg and tracked patients for 68 weeks, average weight loss came to 14.9% of body weight. That's a real, meaningful result. Then SURMOUNT-1 ran tirzepatide at the 15mg dose through 72 weeks and landed at 20.9%. Even tirzepatide's lower doses, 5mg and 10mg, came in at 16% and 19.5% respectively. Semaglutide doesn't match any of those numbers. The comparison isn't close at any dose level.
| Medication | Trial | Avg. Weight Loss | Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | STEP 1 | 14.9% | 68 weeks |
| Tirzepatide (Zepbound) | SURMOUNT-1 | 20.9% (15mg) | 72 weeks |
A 2023 JAMA analysis looked at tirzepatide and semaglutide head to head across dose levels and found tirzepatide ahead across the board. Six percentage points of gap at the highest doses, that's not nothing. For someone at 250 pounds that works out to roughly 15 pounds more weight lost. I don't think patients should dismiss that difference.
But here's what I tell people: those are averages pulled from trial populations, not predictions. I have patients who lost 25% on semaglutide and others who hit a wall at 10% on tirzepatide. The "stronger drug" doesn't produce a guaranteed better outcome for any given person. What it produces is a better average, and you don't know in advance whether you'll land above or below it.
Cost and Access in the Real World
Tirzepatide is newer. In clinical practice that means more prior authorization headaches, less consistent insurance coverage, and fewer pharmacists who've filled it a thousand times. Semaglutide has years of market history behind it, the formularies are better worked out, the savings programs are more established, and the path through insurance tends to be smoother. That doesn't make it the better drug. It just makes it the easier drug to actually start on.
What you end up paying varies enormously depending on your specific insurance and whether you qualify for manufacturer savings. I've had patients get tirzepatide cheaper than semaglutide and vice versa. You really can't predict it without actually running the inquiry. My general advice: if tirzepatide isn't accessible right now, semaglutide is not a consolation prize. Start it, use it, and revisit your options in six months. The drug you can take beats the drug you can't.
Side Effects, Mostly the Same, With One Real Difference
The side effect profiles are largely the same, nausea, GI discomfort, constipation during the titration phase. Most of it settles over the first 8 to 12 weeks as the body adjusts. Going slow on the dose escalation helps significantly, and that's true for both drugs. The thyroid cancer contraindication (medullary thyroid carcinoma, MEN2 syndrome) applies to both equally, worth knowing, worth asking about in the intake.
The one practical difference I notice: tirzepatide's appetite suppression can feel more abrupt. Some patients describe it as a near-complete switch, food interest just drops. Most find that welcome. A small number find it unsettling, like something is off rather than better. Those patients sometimes do better staying on semaglutide, where the appetite reduction feels more gradual. I wouldn't call this a common issue, but I mention it because it comes up, and it's useful to know before you switch and then wonder why you feel strange about eating.
How the Clinical Trial Populations Differed, and Why That Matters
Numbers from separate trials get reported as clean comparisons, but the trial populations were not identical. STEP 1, the STEP 1 trial, enrolled adults with BMI at or above 30, or at or above 27 with a weight related comorbidity. SURMOUNT-1, the SURMOUNT-1 trial, used similar BMI criteria but excluded patients with type 2 diabetes. That exclusion matters because semaglutide's development started on the diabetes side of the aisle, and a meaningful portion of semaglutide prescribing in practice is to patients who have both metabolic disease and weight to lose. Tirzepatide has a diabetes indication too, with its own SURPASS trial program, but the SURMOUNT data set is specifically the non diabetic obesity cohort.
Baseline demographics also differed slightly. STEP 1 enrolled a somewhat older population on average. SURMOUNT-1 enrolled a slightly heavier average baseline weight. Neither difference is huge but both push the clean "14.9 versus 20.9" headline toward apples and oranges. The read of the data is that tirzepatide consistently outperforms semaglutide in the trial data, the effect size is real, but the specific percentages should be taken as ranges rather than exact figures you would expect every patient to land on.
Real world data matching the trials has been accumulating. In observational cohorts, average weight loss at 12 months on semaglutide tends to come in a few points below the STEP 1 number because adherence is imperfect outside of a trial. Tirzepatide numbers similarly come in somewhat below SURMOUNT-1 but the relative ordering, tirzepatide higher than semaglutide, holds. Individual results vary widely around those averages. I have patients who lost 25 percent on semaglutide and patients who lost 10 percent on tirzepatide.
The Switching Question That Keeps Coming Up
The switching question comes up all the time. Patient started on semaglutide a year ago, lost real weight, hit a plateau, now wants to know if tirzepatide would get things moving again. The honest answer depends on where they are in dose escalation and whether that plateau is actually the medication's ceiling, or something else.
If someone has plateaued on a sub-maximal semaglutide dose, the first move is titrating up, not switching. The efficacy data was generated at 2.4mg. Patients sitting at 1.0 or 1.7mg often have meaningful headroom left on the same drug and don't realize it.
For patients at maximum semaglutide who have genuinely plateaued and want more loss, switching to tirzepatide is reasonable. The typical pattern I see when this goes well is an additional 5 to 10 pounds over three to six months as tirzepatide is titrated up. Not everyone responds. Some patients plateau on tirzepatide at a similar weight point because the driver was never the drug, it was the surrounding lifestyle pattern that the drug had reached the limit of what it could offset.
A handful of patients on tirzepatide ask me whether they should switch to semaglutide for specific reasons, usually cost or insurance coverage. That is a legitimate switch and does not usually cost much in terms of weight loss maintenance, because the absolute difference at the maintenance phase is smaller than the difference at the weight loss phase.
The Cardiovascular Data So Far
Both drugs have cardiovascular outcomes data that matters for patients with risk factors beyond weight. Semaglutide picked up an FDA approval in 2024 for reducing major adverse cardiovascular events in adults with CVD and overweight or obesity, SELECT trial. That's a meaningful separate indication, and it's started to move insurance coverage in ways the obesity indication alone hadn't managed to.
Tirzepatide has cardiovascular outcomes data from SURPASS-CVOT, ongoing and expected to read out through 2026 and 2027. Early signals on cardiometabolic markers look positive, but tirzepatide doesn't have a formal MACE-reduction FDA approval yet. For a patient whose insurance access depends on the cardiovascular indication, semaglutide currently has the cleaner argument.
Which One to Choose
If maximum weight loss is the goal, injections aren't a problem, and access isn't a barrier, tirzepatide. That's not a close call based on current evidence, and I'd rather say it directly than frame this as a coin flip. It's the strongest approved weight loss medication we have right now.
Semaglutide is a solid first choice when tirzepatide isn't accessible, when insurance coverage favors it, or when a patient wants the more extensively studied drug before trying something newer. Moving to tirzepatide later is always an option. Starting with semaglutide and adjusting isn't a failure, honestly, that's often how the most successful long term plans I've seen have played out.
One more thing: if a patient genuinely won't do injections, this entire comparison becomes irrelevant. The conversation shifts entirely to oral options, Oral Wegovy and Foundayo, which have their own distinct trade offs. That's a separate decision tree, and worth working through on its own terms if that's where someone is.
